Ghrelin (human) |
| Catalog No.GC16346 |
Ghrelin (human) was isolated from the gut of both human and rat as the endogenous ligand of the growth hormone secretagogue receptor (GHS-R), and has an effection on the activity of arcute neurones with a much stronger affinity (IC50, 0.3×10-9M) than GHSR antagonist (D-Lys3)-GHRP-6 (IC50, 0.9×10-6M).
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 258279-04-8
Sample solution is provided at 25 µL, 10mM.
Ghrelin (human) was isolated from the gut of both human and rat as the endogenous ligand of the growth hormone secretagogue receptor (GHS-R), and has an effection on the activity of arcute neurones with a much stronger affinity (IC50, 0.3×10-9M) than GHSR antagonist (D-Lys3)-GHRP-6 (IC50, 0.9×10-6M) [1]. The highest levels of ghrelin are secreted from the X/A - like cells of the oxyntic glands located in the gastric fundus, with lower levels widely distributed throughout the body [2]. Ghrelin is secreted direct into the local gastric circulation and transported to the brain directly, requiring it to either cross the blood-brain barrier via a saturated transport system or via the blood stream to enter areas of the brain that are not protected by the blood-brain barrier [3]. Ghrelin modulates the hypothalamic arcuate nucleus, in an indirect manner, via activation of the vagus nerve and brain stem nuclei [4]. Ghrelin has a homeostatic role that encompasses multiple areas of the body, with actions that include downregulation of brown adipose tissue thermogenesis [5-7], modulation of non-hypothalamic brain regions producing an increased taste sensation [7] and stimulation of gastric emptying and motility [8]. The actions of ghrelin may contribute to the development of T2DM and obesity [9].
Differentiating visceral adipocytes were exposed to increasing concentrations of acylated (human) and desacyl ghrelin (0.1-1000 pmol l-1) for 48 h, and induced a significant increase in PPARG and SREBF1 transcript levels, the proportion of cells positive for lipid droplets was markedly increased in the presence of both ghrelin forms, compared with the cells in the differentiation medium without ghrelin [10].
References:
[1]. Traebert M, Riediger T, Whitebread S, et al. Ghrelin acts on leptin‐responsive neurones in the rat arcuate nucleus[J]. Journal of neuroendocrinology, 2002, 14(7): 580-586.
[2]. Dixit V D, Schaffer E M, Pyle R S, et al. Ghrelin inhibits leptin-and activation-induced proinflammatory cytokine expression by human monocytes and T cells[J]. The Journal of clinical investigation, 2004, 114(1): 57-66.
[3]. Angelidis G, Valotassiou V, Georgoulias P. Current and potential roles of ghrelin in clinical practice[J]. Journal of endocrinological investigation, 2010, 33(11): 823-838.
[4]. Date Y, Murakami N, Toshinai K, et al. The role of the gastric afferent vagal nerve in ghrelin-induced feeding and growth hormone secretion in rats[J]. Gastroenterology, 2002, 123(4): 1120-1128.
[5]. Tsubone T, Masaki T, Katsuragi I, et al. Ghrelin regulates adiposity in white adipose tissue and UCP1 mRNA expression in brown adipose tissue in mice[J]. Regulatory peptides, 2005, 130(1-2): 97-103.
[6]. Whittle A J, LÓpez M, Vidal-Puig A. Using brown adipose tissue to treat obesity-the central issue[J]. Trends in molecular medicine, 2011, 17(8): 405-411.
[7]. Mano-Otagiri A, Iwasaki-Sekino A, Nemoto T, et al. Genetic suppression of ghrelin receptors activates brown adipocyte function and decreases fat storage in rats[J]. Regulatory peptides, 2010, 160(1-3): 81-90.
[8]. Masuda Y, Tanaka T, Inomata N, et al. Ghrelin stimulates gastric acid secretion and motility in rats[J]. Biochemical and biophysical research communications, 2000, 276(3): 905-908.
[9]. MÜller T D, Nogueiras R, Andermann M L, et al. Ghrelin[J]. Molecular metabolism, 2015, 4(6): 437-460.
[10]. RodrÍguez A, GÓmez-Ambrosi J, CatalÁn V, et al. Acylated and desacyl ghrelin stimulate lipid accumulation in human visceral adipocytes[J]. International journal of obesity, 2009, 33(5): 541-552.
| Cell experiment [1]: | |
|
Cell lines |
Human stromovascular fraction cells (SVFCs) |
|
Preparation Method |
Adipocyte differentiation was initiated when cells reached ∼80-90% confluence. Cells were stimulated with differentiation medium I (adipocyte medium supplemented with 10% NCS, 0.5 mmol l-1 3-isobutyl-1-methylxanthine, 0.1 µmol l-1 dexamethasone and 10 µg ml-1 insulin) for 2 days. Furthermore, the cells were then switched to differentiation medium II (adipocyte medium supplemented with 10% NCS and 10 µg ml-1 insulin) for another 6 days and media were changed every 2 days. Adipocytes were 70-75% differentiated (as determined by morphology) in the eighth day of differentiation. They were incubated for 2 h in a serum-free adipocyte medium and, then, stimulated with different concentrations of acylated Ghrelin (human) or with desacyl ghrelin (0.1, 1, 10, 100 and 1000 pmol l-1) for 48 h. One sample per experiment was used for obtaining control responses in the presence of a solvent. |
|
Reaction Conditions |
0.1, 1, 10, 100 and 1000 pmol l-1 for 48 hours |
|
Applications |
The addition of acylated and desacyl ghrelin during adipocyte differentiation induced a significant increase in PPARG and SREBF1 transcript levels. |
|
References: [1]: RodrÍguez A, GÓmez-Ambrosi J, CatalÁn V, et al. Acylated and desacyl ghrelin stimulate lipid accumulation in human visceral adipocytes[J]. International journal of obesity, 2009, 33(5): 541-552. |
|
| Cas No. | 258279-04-8 | SDF | |
| Formula | C149H249N47O42 | M.Wt | 3370.9 |
| Solubility | Soluble in Water | Storage | Desiccate at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 0.2967 mL | 1.4833 mL | 2.9666 mL |
| 5 mM | 0.0593 mL | 0.2967 mL | 0.5933 mL |
| 10 mM | 0.0297 mL | 0.1483 mL | 0.2967 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 21 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *